A Medical Device Daily

VeriChip (Delray Beach, Florida) and its development partner Receptors (Chaska, Minnesota) reported that VeriChip has received an exclusive license to Receptors' Patent No. 7,504,364 titled "Methods of Making Arrays and Artificial Receptors" and Patent No. 7,469,076 "Sensors Employing Combinatorial Artificial Receptors," to use in conjunction with VeriChip's Patent No. 7,125,382 entitled "Embedded Bio-Sensor System," to develop an in vivo glucose-sensing RFID microchip.

VeriChip's patent for an "Embedded Bio-Sensor System" covers a bio-sensor system that uses radio frequency identification technology and that includes a remote transponder in wireless communication with an implantable passively-powered on-chip transponder. The bio-sensor system is specifically adapted to provide a substantially stable and precise sensor reference voltage to a sensor assembly that is included with the on-chip transponder. The remote transponder is also configured to remotely receive data representative of a physiological parameter of the patient as well as identification data and may enable readout of one or more of the physiological parameters that are measured, processed and transmitted by the on-chip transponder upon request by the remote transponder.

The successful development of VeriChip's glucose-sensing microchip could negate the need for diabetics to draw blood samples multiple times each day to read their blood glucose levels. Instead, VeriChip believes that patients implanted with the glucose-sensing microchip, if successfully developed, could get a rapid reading of their blood sugar with a simple wave of a handheld scanner.